What did @loganshults_ actually say?
The creator reports nearly 60 days of oral BPC-157 at 500 micrograms daily, crediting it with eliminating the joint pain he normally experiences from cardio and performance-enhancing drug use. He also claims his digestion is holding up well and that his CRP inflammation marker came back "in range" at one week, when he expected it to be elevated. He is transparent that he uses PEDs and acknowledges BPC-157 does not affect cortisol, which was elevated on his labs.
Credit where it is due: he does not claim BPC-157 cured anything, he acknowledges confounding variables, and he frames this explicitly as ongoing self-experimentation. That is more intellectual honesty than most peptide content on this platform. Still, there are real problems with how he interprets his own data, and several implicit claims deserve scrutiny.
Does the science back this up?
The short answer is: partially, in animal models, and not at all in oral human trials, because those trials essentially do not exist yet. BPC-157 is a synthetic pentadecapeptide derived from a gastric protein. Its anti-inflammatory and tissue-repair effects in rodent studies are genuinely interesting. But "interesting in rats" and "proven in humans taking it orally" are two very different sentences.
Sikiric et al. (2018, Current Pharmaceutical Design) documented significant anti-inflammatory and gastroprotective effects of BPC-157 in animal models, including reduction in NF-kB activity and nitric oxide pathway modulation. Gwyer et al. (2019, Current Opinion in Pharmacology) acknowledged the peptide's potential but noted the near-total absence of human pharmacokinetic data. The specific problem with oral administration is stability: digestive enzymes may degrade the peptide before systemic absorption occurs, though some researchers argue the gastrointestinal tract itself may be the relevant target for local effects.
What did they get wrong (or right)?
The CRP interpretation is the weakest part of this video. He says his CRP was "in range when you would expect it to be elevated" and attributes that to BPC-157. That is not how you read a single lab value with no baseline, no control condition, and multiple simultaneous variables. He was also using PEDs, which can have their own complex effects on inflammatory markers. One CRP result at one time point proves nothing about causation.
The joint pain claim is also a subjective outcome with no control. He acknowledges his joints typically hurt at four weeks, but pain perception is heavily influenced by expectation and placebo response. He got something right though: he correctly stated BPC-157 does not help with cortisol, which matches the literature. That distinction matters and most creators would have oversold it. His digestion claim is actually the most biologically plausible of all his claims, since BPC-157's strongest mechanistic support involves the gut lining itself (Sikiric et al., 2016, Journal of Physiology).
What should you actually know?
BPC-157 is not FDA-approved for any indication. It is available through compounding pharmacies in the United States under specific regulatory frameworks, but its legal and clinical status is actively evolving. The FDA issued warnings about certain compounded peptides in 2023, and the regulatory environment can change. If you are considering peptide therapy, that conversation belongs with a licensed clinician who can review your actual health history, not a 60-second self-report from someone who also uses PEDs.
The oral versus injectable bioavailability question is genuinely unresolved. Some researchers propose that oral BPC-157 acts locally in the GI tract rather than systemically, which would make the joint pain and systemic inflammation claims harder to explain mechanistically. There is no peer-reviewed human trial establishing the systemic bioavailability of oral BPC-157 at any dose. Anecdote, even a detailed one, is not a substitute for that data. Be skeptical of content that treats n=1 self-reporting as clinical evidence, including this video.